Xonrid®预防治疗乳腺及头颈肿瘤放疗所致急性放射性皮炎的随机对照研究
这项单中心、开放标签、两臂随机对照研究比较Xonrid®局部医疗设备与标准护理(SOC)在头颈癌(HNC)和乳腺癌(BC)放疗患者中预防和治疗急性放射性皮炎(ARD)的效果。
要点
- BC组第5周未出现G2 ARD的比例在Xonrid®+SOC组更高(p=0.091),但未达主要终点。
- BC组中Xonrid®+SOC的G2 ARD发生时间显著长于单用SOC组(p<0.0491)。
- HNC组呈现相似趋势但未达统计学显著性。
核心结论
- 尽管主要终点未达成,Xonrid®可能作为预防和治疗ARD的有效医疗设备,至少在BC患者中可延迟皮肤毒性发生时间并减少G2 ARD比例。
研究设计与样本
- 单中心、开放标签、两臂随机对照研究,1:1随机分配HNC和BC患者接受Xonrid®+SOC或单用SOC。
- BC患者均接受三维适形放疗(3D-CRT),HNC患者均接受容积旋转调强放疗(VMAT)。
- 患者从放疗第1天起每日三次在照射区域涂抹Xonrid®,直至放疗结束后2周或出现≥3级皮肤毒性。
- 主要终点为第5周两组ARD分级<2的患者比例;次要终点包括G2皮肤毒性发生中位时间、皮肤红斑和色素沉着变化、经皮水分丢失(TEWL)及患者报告的皮肤症状。
主要发现
- 第5周BC组未出现G2 ARD的比例在Xonrid®+SOC组更高(p=0.091)。
- BC组中Xonrid®+SOC的G2 ARD发生时间显著长于单用SOC组(p<0.0491)。
- HNC组呈现相似趋势但未达统计学显著性。
- 两癌种中,Xonrid®+SOC组患者的生活质量(Skindex-16评分)始终更低。
关键数值与推荐
- 主要终点:第5周ARD分级<2的患者比例,BC组p=0.091,未达统计学显著。
- BC组G2 ARD发生时间比较p<0.0491。
- 生活质量评估采用Skindex-16问卷,Xonrid®+SOC组评分始终更低。
临床怎么用
- 对于接受放疗的BC患者,可考虑使用Xonrid®联合SOC以延迟G2放射性皮炎的发生并减少其比例。
- HNC患者使用Xonrid®的获益趋势相似但未达统计学显著,需结合个体情况判断。
- 使用Xonrid®时需关注患者生活质量评分的变化。
局限性
- 研究为单中心、开放标签设计,可能存在偏倚。
- 主要终点未达到统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was an open-label, 2-arms, monocentric, randomized clinical trial comparing Xonrid®, a topical medical device, versus standard of care (SOC) in preventing and treating acute radiation dermatitis (ARD) in Head and Neck Cancer (HNC) and Breast Cancer (BC) patients undergoing radiotherapy (RT). METHODS: Eligible HNC and BC patients were randomized 1:1 to receive Xonrid® + SOC or SOC during RT. Patients were instructed to apply Xonrid® on the irradiated area three times daily, starting on the first day of RT and until 2 weeks after RT completion or until the development of grade ≥ 3 skin toxicity. The primary endpoint was to evaluate the proportion of patients who developed an ARD grade < 2 at the 5th week in both groups. Secondary endpoints were median time to grade 2 (G2) skin toxicity onset; changes in skin erythema and pigmentation and trans-epidermal water loss (TEWL); patient-reported skin symptoms. All patients were evaluated at baseline, weekly during RT and 2 weeks after treatment completion. The evaluation included: clinical toxicity assessment; reflectance spectrometry (RS) and TEWL examination; measurement of patients' quality of life (QoL) through Skindex-16 questionnaire. RESULTS: Eighty patients (40 for each cancer site) were enrolled between June 2017 and July 2018. Groups were well balanced for population characteristics. All BC patients underwent 3-Dimensional Conformal RT (3D-CRT) whereas HNC patients underwent Volumetric-Modulated Arc Therapy (VMAT). At week 5 the proportion of BC patients who did not exhibit G2 ARD was higher in Xonrid® + SOC group (p = 0.091). In the same group the onset time of G2 ARD was significantly longer than in SOC-alone group (p < 0.0491). For HNC groups there was a similar trend, but it did not reach statistical significance. For both cancer sites, patients' QoL, measured by the Skindex-16 score, was always lower in the Xonrid® + SOC group. CONCLUSION: Despite the failure to achieve the primary endpoint, this study suggests that Xonrid® may represent a valid medical device in the prevention and treatment of ARD at least in BC patients, delaying time to develop skin toxicity and reducing the proportion of patients who experienced G2 ARD during RT treatment and 2 weeks later. TRIAL REGISTRATION: The study was approved by the Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT 52/14 - NCT02261181 ). Registered on ClinicalTrial.gov on 21st August 2017.
引用
- Ingargiola R, De Santis MC, Iacovelli NA, et al. A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. Radiat Oncol. 2020. PMID: 32791985. doi:10.1186/s13014-020-01633-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。